| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Musket David B is a Director at CAPR. Recent filings cover 5 purchases and 2 sales. Those positions are worth an estimated $321K at current prices.
Our model assigns Musket David B a middling insider score of 60/100, based on 5 past trades. Over a 12-month horizon, 60.0% of those trades were profitable, with an average 12-month return of +52.1%.
Musket David B's largest disclosed position is in CAPR as Director, worth about $321K. Net of sales, the recent Form 4 record there shows accumulation of 57,965 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 12, 2023 | CAPR Capricor Therapeutics, Inc. | Director | Buy | 410 | $2.75 | $1,127.50 | +1.3% | +84.5% | +527.9% | |
| Oct 9, 2023 | CAPR Capricor Therapeutics, Inc. | Director | Buy | 5,083 | $2.82 | $14,334.06 | +19.5% | +92.4% | +595.3% | |
| Oct 4, 2023 | CAPR Capricor Therapeutics, Inc. | Director | Buy | 2,500 | $2.90 | $7,250.00 | +10.6% | +80.3% | +501.1% | |
| Jun 29, 2022 | CAPR Capricor Therapeutics, Inc. | Director | Sale+OE | 28,215 | $3.77 | $106,370.55 | -68.9% | +54.0% | +27.7% | |
| Jun 27, 2022 | CAPR Capricor Therapeutics, Inc. | Director | Sell | 17,775 | $4.44 | $78,921.00 | -30.3% | +30.6% | +12.0% | |
| May 9, 2017 | CAPR Capricor Therapeutics, Inc. | Director | Buy | 25,000 | $3.10 | $77,500.00 | New | - | - | |
| Jan 21, 2015 | CAPR Capricor Therapeutics, Inc. | Director | Buy | 70,962 | $3.52 | $249,999.13 | New | - | - |